A Phase I, Multicenter, Open-label, Dose Escalation Study of Intravenous Administration of VCN-01 Oncolytic Adenovirus With or Without Gemcitabine and Abraxane® in Patients With Advanced Solid Tumors

Trial Profile

A Phase I, Multicenter, Open-label, Dose Escalation Study of Intravenous Administration of VCN-01 Oncolytic Adenovirus With or Without Gemcitabine and Abraxane® in Patients With Advanced Solid Tumors

Recruiting
Phase of Trial: Phase I

Latest Information Update: 08 Jul 2017

At a glance

  • Drugs VCN 01 (Primary) ; Gemcitabine; Paclitaxel
  • Indications Adenocarcinoma; Gastrointestinal stromal tumours; Head and neck cancer; Pancreatic cancer; Solid tumours
  • Focus Adverse reactions; First in man
  • Sponsors VCN Biosciences
  • Most Recent Events

    • 30 Jan 2017 Planned End Date changed from 1 Dec 2017 to 1 May 2018.
    • 30 Jan 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Dec 2017.
    • 02 Dec 2016 Results (n=23) presented at the 28th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top